Corvus Pharmaceuticals: Assessing the Impact of Cash Burn on the Company's Cash Runway

Corvus Pharmaceuticals has a cash runway of about 2.0 years, based on its November 2025 balance sheet and cash burn of $32m in the last year. Analysts predict the company will reach cashflow breakeven in 4 years. While the company's cash burn has increased by 46% over the last year, management is investing in future growth, and its true cash runway will be shorter if spending continues to rise.